|
|
|
16.11.26 - 02:00
|
INSILICO Repurchases 300,000 Shares Last Fri for Over HKD11.2 million (AAStocks)
|
|
|
INSILICO (03696.HK) announced that it repurchased 300,000 shares last Fri (13th), at prices ranging from HKD37.2 to HKD37.5 per share, involving approximately HKD11.2033 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the authoritat......
|
|
|
|
|
10.11.26 - 02:15
|
INSILICO Spends HKD7.562 Million to Buy Back 199,000 Shares on Mon (AAStocks)
|
|
|
INSILICO (03696.HK) announced that it repurchased 199,000 shares on Nov 9 at HKD38 per share, involving approximately HKD7.562 million. Since the repurchase mandate resolution was approved on Jun 2, 2026, the group has cumulatively repurchased 599,000 shares, accounting for 0.1046% of issued shares. (da)~AASTOCKS Financial NewsW......
|
|
|
09.11.26 - 01:45
|
INSILICO Repurchased 400,000 Shares Last Fri for HKD15.0059 million (AAStocks)
|
|
|
INSILICO (03696.HK) announced that it repurchased 400,000 shares on November 6 at prices ranging from HKD36.921 to HKD38.3 per share, involving approximately HKD15.0059 million.Since the ordinary resolution was passed on June 2, 2026, the group has cumulatively repurchased 400,000 shares, representing 0.0699% of its issued share......
|
|
|
|
|
|
|
|
|
|
|
30.09.26 - 06:30
|
INSILICO Nominates Next-Generation Small Molecule GIPR Antagonist (AAStocks)
|
|
|
INSILICO (03696.HK) announced the nomination of ISM1354 as a preclinical candidate compound (PCC), with potential applications in interventions for obesity, type 2 diabetes and related diseases, and possible expansion into the cardiovascular disease field. The company has announced the nomination of 10 PCCs in the first nine mon......
|
|
|
|
|
|
|
|
|
18.09.26 - 06:30
|
Research: Daiwa: INSILICO BD and PCC Output Hit Record High (AAStocks)
|
|
|
Daiwa released a report saying that INSILICO (03696.HK) achieved record-high BD and PCC output, while its revenue surge in 1H26 was mainly driven by accelerated out-licensing activities. Revenue in the first half of the year jumped 287.2% YoY to USD106 million, supported by strong growth in its core drug discovery and pipeline d......
|
|
|
|
|
10.09.26 - 05:30
|
An AI-Designed Drug Just Moved Six Different Aging Clocks At Once (ZeroHedge)
|
|
|
An AI-Designed Drug Just Moved Six Different Aging Clocks At Once
An experimental drug designed using AI has produced measurable shifts toward a younger biological-age profile in patients.
Developed by Insilico Medicine, the drug - rentosertib - was initially engineered to treat idiopathic pulmonary fibrosis (IPF), a progressive, age-associated lung-scarring disease. When researchers analyzed blood samples from a Phase IIa clinical trial, they applied six proteomic profiling "aging clocks" among 42 participants. All six detected reductions in predicted biological age, whereas the placebo group showed little change or slight increases. The most pronounced and consistent effects emerged around week four of treatment.
The study was authored by Insilico with academic collaborators from Harvard, Stanford, the Broad Institute, RWTH Aachen, Peking University and Westlake University.
Insilico used AI not only to identify a specific enzyme (TNIK) linked to both fibrosis and aging pathways, ...
|
|
|
|
|
|
|
|
|
|
|
|